N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
In most cases, the targeted microbubble contrast agents (MCAs) are fitted with a high-affinity targeting ligand. After the MCAs are adhered to the target, they begin to improve the acoustic signal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback